Journal
Molecular Therapy-Methods & Clinical Development
Publication Date
2021
Volume
20
First Page
497
Last Page
507
Document Type
Open Access Publication
DOI
10.1016/j.omtm.2020.12.014
Rights and Permissions
White, K. A., Nelvagal, H. R., Poole, T. A., Lu, B., Johnson, T. B., Davis, S., . . . Weimer, J. M. (2021). Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-batten disease mice. Molecular Therapy - Methods and Clinical Development, 20, 497-507. doi:10.1016/j.omtm.2020.12.014 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
White, Katherine A.; Nelvagal, Hemanth R.; Poole, Timothy A.; Lu, Bin; Johnson, Tyler B.; Davis, Samantha; Pratt, Melissa A.; Brudvig, Jon; Assis, Ana B.; Likhite, Shibi; Meyer, Kathrin; Kaspar, Brian K.; Cooper, Jonathan D.; Wang, Shaomei; and Weimer, Jill M., "Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice." Molecular Therapy-Methods & Clinical Development. 20, 497 - 507. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10109